Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2016 09:08 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies

Patient-friendly platform treats allergies while a patient brushes their teeth Oral mucosal route of administration demonstrated to be efficacious No gastrointestinal side effects...
March 01, 2016 07:10 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy

New York, March 01, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced...
February 22, 2016 07:15 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics to Present at New York Venture Capital Association 2016 Health & Bio Technology Summit

New York, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
December 29, 2015 09:41 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics to Participate in Meetings with the Investment Community During the 34th Annual JP Morgan Healthcare Conference, January 11-14, 2016

New York, NY, Dec. 29, 2015 (GLOBE NEWSWIRE) -- Intrommune Therapeutics (“Intrommune”), a New York City-based biotechnology company developing patient-friendly therapies for food allergy, today...

keyboard_arrow_left Previous Page